| answer text |
<p>Cannabis-based products for medicinal use were rescheduled on 1 November 2018 to
allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe
cannabis-based products for medicinal use, where clinically appropriate and in the
best interest of patients.</p><p>NHS England and NHS Improvement is using extant systems
to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal
use in England. In England, these systems monitor the number of items dispensed and
associated costs in primary care and the volume of products used and associated cost
in secondary care. NHS England’s and NHS Improvement’s Controlled Drug Accountable
Officers are also collecting local intelligence in both the National Health Service
and independent sector.</p><p> </p>
|
 |
